Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	11/18/2004 3:04:41 AM
	of 52153

Biocon, Vaccinex in partnership for antibodies Wed Nov 17, 2004 11:52 PM ET BOMBAY, Nov 18 (Reuters) - Indian biotech firm Biocon Ltd. (BION.BO: Quote, Profile, Research) said on Thursday it has entered into a partnership with U.S.-based privately-held biotechnology firm Vaccinex Inc. to co-develop at least four therapeutic antibody products. Biocon will also make an equity investment in Vaccinex, it said, without revealing details. The two firms will work on antibody products for cancer, inflammation and autoimmune diseases. [Interesting deal. An Indian company funding a US colleague and gaining technology access the same time].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next